{"id":"biological-solrikitug-low-dose","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Solrikitug works by inhibiting the activity of IL-1β, a pro-inflammatory cytokine involved in the pathogenesis of various inflammatory diseases. By blocking IL-1β, solrikitug aims to reduce inflammation and alleviate symptoms associated with these conditions.","oneSentence":"Solrikitug is a low-dose biological drug that targets the IL-1β pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:24:20.609Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of systemic juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT06496620","phase":"PHASE2","title":"A Study to Evaluate Solrikitug in Participants With COPD (ZION)","status":"RECRUITING","sponsor":"Uniquity One (UNI)","startDate":"2024-08-14","conditions":"COPD","enrollment":171}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38955,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Biological: Solrikitug low dose","genericName":"Biological: Solrikitug low dose","companyName":"Uniquity One (UNI)","companyId":"uniquity-one-uni","modality":"Biologic","firstApprovalDate":"","aiSummary":"Solrikitug is an antibody being studied in a clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). The trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of low-dose Solrikitug in participants with COPD.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}